Cargando…
Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
BACKGROUND: Current guidelines recommend non-vitamin‑K oral anticoagulants (NOACs) as the first-choice therapy for stroke prevention in patients with atrial fibrillation (AF). The use of drugs in a clinical trial setting differs from that in real-world populations. Real-world data are important to a...
Autores principales: | de Veer, A. J. W. M., Bennaghmouch, N., Wijffels, M. C. E. F., ten Berg, J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890914/ https://www.ncbi.nlm.nih.gov/pubmed/31773474 http://dx.doi.org/10.1007/s12471-019-01330-y |
Ejemplares similares
-
The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023) -
Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021) -
NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017) -
Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020) -
Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
por: Noseworthy, Peter A., et al.
Publicado: (2017)